COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
10/03/2026
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed [...]
Longeveron Announces Private Placement of up to $30 Million
10/03/2026
$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules [...]
Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000
10/03/2026
CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has entered [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026
— The new pricing structure is made available as of February for 3.39 EUR per day at pharmacies throughout Finland AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026
— The new pricing structure is made available as of February for 566,13 ISK per day at pharmacies throughout Iceland AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
Egg Medical Presents CRT 2026 Data Demonstrating a Responsible Path to Light Lead and Lead-Apron Free Protection
10/03/2026
WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Egg Medical, a leader in enhanced radiation protection devices (ERPD), today announced the results of a Late-Breaking Trial presented at the Cardiovascular Research [...]
HealthEdge HealthRules® Payer Works with AWS to Set a New Scalability Benchmark, Expanding to Support Health Plans with More Than 40 Million Members
10/03/2026
Platform advancements running on AWS position HealthEdge customers to meet future healthcare demands and growth BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- HealthEdge® , the technology and services company powering [...]
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
10/03/2026
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for [...]
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
10/03/2026
-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE [...]
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
10/03/2026
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics [...]
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
10/03/2026
ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatment Children ages 2-5 who achieved disease clearance and who switched to proactive twice- [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026
— The new pricing structure is made available as of February for 26,63 DKK per day at pharmacies throughout Denmark AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026
— The new pricing structure is made available as of February for 32,13 SEK per day at pharmacies throughout Sweden AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
Imprivata Introduces Agentic Identity Management to Secure and Govern AI Agents in Healthcare
10/03/2026
New capabilities enable healthcare organizations to deploy AI agents that improve clinician productivity while maintaining secure, compliant access across modern and legacy systems WALTHAM, Mass., March 10, 2026 (GLOBE [...]
Nominations Now Open for PerfectServe’s Sixth Annual Nurses of Note Awards Program
10/03/2026
2026 program to highlight nurse leadership and excellence in clinical innovation, patient-centered care, culture & retention, and care team communication MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a [...]
Assemblée générale annuelle 2026 de Roche
10/03/2026
Adoption de toutes les propositions du Conseil d’administration Réélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil d’administration qui se sont [...]
Roche Annual General Meeting 2026
10/03/2026
Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed 39th consecutive dividend [...]
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
10/03/2026
Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophy BLA supported by positive pivotal HOPE-3 Phase 3 results, including achievement [...]
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
10/03/2026
Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophy BLA supported by positive pivotal HOPE-3 Phase 3 results, including achievement [...]

Pages